Cardiac Contractility Modulation (CCM) Implant
Heart Failure with Reduced Ejection Fraction (HFrEF)
Pre-clinical / Early ClinicalActive
Key Facts
Indication
Heart Failure with Reduced Ejection Fraction (HFrEF)
Phase
Pre-clinical / Early Clinical
Status
Active
Company
About Berlin Heals
Berlin Heals is a private, pre-revenue medical device innovator targeting the large and growing heart failure market. Its core technology is the Cardiac Contractility Modulation (CCM) implant, designed to improve the heart's pumping strength in patients with reduced ejection fraction. The company is advancing its device through clinical development in Europe, positioning itself in a competitive landscape dominated by pharmaceutical and device-based therapies. Success hinges on clinical validation, regulatory approval, and eventual market adoption against established treatments.
View full company profileTherapeutic Areas
Other Heart Failure with Reduced Ejection Fraction (HFrEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | FDA Approved / PMA |
| ALLAY-HFrEF | Alleviant Medical | Pivotal Trial |
| Neucardin® | Zensun Sci & Tech | Phase 2/3 |
| SRD001 (inferred) | Sardocor | Phase 1 |
| Undisclosed HFrEF Program | NanoPhoria Bioscience | Preclinical |
| Firibastat (QGC001) | Quantum Genomics | Phase 2a |
| AC01 | AnaCardio | Phase 2 |
| Omecamtiv Mecarbil | Cytokinetics | Phase 3 |